Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia

Journal of Lipid Research

Volumn 53, Issue 11, 2012, Pages 2425-2428

  Ma, Li ^a   Ballantyne, Christie M ^b   Belmont, John W ^b   Keinan, Alon ^a   Brautbar, Ariel ^b,c  

^a Program on Infrastructure Policy   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MARSHFIELD CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL; APOLIPOPROTEIN B; ATORVASTATIN; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; STATIN; VERY LOW DENSITY LIPOPROTEIN;

ANGPTL3 GENE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DYSLIPIDEMIA; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE INTERACTION; GENE NUMBER; GENETIC SCREENING; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RXRA GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOPOIETINS; APOLIPOPROTEINS; APOLIPOPROTEINS B; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 84867348598     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M028829     Document Type: Article

References (29)

1. van Raalte, D. H., M. Li, P. H. Pritchard, and K. M. Wasan. 2004. Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future. Pharm. Res. 21: 1531-1538. (Pubitemid 41184380)
2. Brautbar, A., D. Covarrubias, J. Belmont, F. Lara-Garduno, S. S. Virani, P. H. Jones, S. M. Leal, and C. M. Ballantyne. 2011. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 219: 737-742.
3. Lai, C-Q., D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, M. A. Province, et al. 2007. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27: 1417-1425. (Pubitemid 46809433)
4. Brautbar, A., S. S. Virani, J. Belmont, V. Nambi, P. H. Jones, and C. M. Ballantyne. 2012. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J. Lipid Res. 53: 556-560.
5. Ma, L., A. Brautbar, E. Boerwinkle, C. F. Sing, A. G. Clark, and A. Keinan. 2012. Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations. PLoS Genet. In press.
6. Ma, L., J. Yang, H. B. Runesha, T. Tanaka, L. Ferrucci, S. Bandinelli, and Y. Da. 2010. Genome-wide association analysis of total cholesterol and high-density lipoprotein cholesterol levels using the Framingham heart study data. BMC Med. Genet. 11: 55.
7. Jones, P. H., M. H. Davidson, M. L. Kashyap, M. T. Kelly, S. M. Buttler, C. M. Setze, D. J. Sleep, and J. C. Stolzenbach. 2009. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis. 204: 208-215.
8. Jones, P. H., H. E. Bays, M. H. Davidson, M. T. Kelly, S. M. Buttler, C. M. Setze, D. J. Sleep, and J. C. Stolzenbach. 2008. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin. Drug Investig. 28: 625-634.
9. Kane, J. P., and R. J. Havel. 2001. Disorders of the biogenesis and secretion of lipoproteins containing the B-apolipoproteins. In The Metabolic Basis of Inherited Disease. C. R. Scriver, A. L. Beaudet, D.Valle, and W. S. Sly, editors. McGraw-Hill, New York. 2717-2752.
10. Kathiresan, S., C. J. Willer, G. M. Peloso, S. Demissie, K. Musunuru, E. E. Schadt, L. Kaplan, D. Bennett, Y. Li, T. Tanaka, et al. 2009. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41: 56-65.
11. Willer, C. J., S. Sanna, A. U. Jackson, A. Scuteri, L. L. Bonnycastle, R. Clarke, S. C. Heath, N. J. Timpson, S. S. Najjar, H. M. Stringham, et al. 2008. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40: 161-169. (Pubitemid 351171403)
12. Spirin, V., S. Schmidt, A. Pertsemlidis, R. S. Cooper, J. C. Cohen, and S. R. Sunyaev. 2007. Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. Am. J. Hum. Genet. 81: 1298-1303. (Pubitemid 350211459)
13. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788. (Pubitemid 351846853)
14. Cordell, H. J. 2002. Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. Hum. Mol. Genet. 11: 2463-2468. (Pubitemid 35174710)
15. Moskvina, V., and K. M. Schmidt. 2008. On multiple testing correction in genome wide association studies. Genet. Epidemiol. 32: 567-573.
16. Becker, T., C. Herold, C. Meesters, M. Mattheisen, and M. P. Baur. 2011. Significance levels in genome-wide interaction analysis (GWIA). Ann. Hum. Genet. 75: 29-35.
17. Inoue, I., F. Itoh, S. Aoyagi, S. Tazawa, H. Kusama, M. Akahane, T. Mastunaga, K. Hayashi, T. Awata, T. Komoda, et al. 2002. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem. Biophys. Res. Commun. 290: 131-139. (Pubitemid 34694475)
18. Kathiresan, S., O. Melander, C. Guiducci, A. Surti, N. P. Burtt, M. J. Rieder, G. M. Cooper, C. Roos, B. F. Voight, A. S. Havulinna, et al. 2008. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40: 189-197. (Pubitemid 351171402)
19. Wang, J., M. R. Ban, G. Y. Zou, H. Cao, T. Lin, B. A. Kennedy, S. Anand, S. Yusuf, M. W. Huff, R. L. Pollex, et al. 2008. Polygenic determinants of severe hypertriglyceridemia. Hum. Mol. Genet. 17: 2894-2899.
20. Sabatti, C., S. K. Service, A. L. Hartikainen, A. Pouta, S. Ripatti, J. Brodsky, C. G. Jones, N. A. Zaitlen, T. Varilo, M. Kaakinen, et al. 2009. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat. Genet. 41: 35-46.
21. Chasman, D. I., G. Pare, R. Y. Zee, A. N. Parker, N. R. Cook, J. E. Buring, D. J. Kwiatkowski, L. M. Rose, J. D. Smith, P. T. Williams, et al. 2008. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ. Cardiovasc. Genet. 1: 21-30.
22. Noto, D., A. B. Cefalu, V. Valenti, F. Fayer, E. Pinotti, M. Ditta, R. Spina, G. Vigna, P. Yue, S. Kathiresan, et al. 2012. Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia. Arterioscler. Thromb. Vasc. Biol. 32: 805-809.
23. Musunuru, K., J. P. Pirruccello, R. Do, G. M. Peloso, C. Guiducci, C. Sougnez, K. V. Garimella, S. Fisher, J. Abreu, A. J. Barry, et al. 2010. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N. Engl. J. Med. 363: 2220-2227.
24. Romeo, S., W. Yin, J. Kozlitina, L. A. Pennacchio, E. Boerwinkle, H. H. Hobbs, and J. C. Cohen. 2009. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J. Clin. Invest. 119: 70-79.
25. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58. (Pubitemid 32095642)
26. Inaba, T., M. Matsuda, M. Shimamura, N. Takei, N. Terasaka, Y. Ando, H. Yasumo, R. Koishi, M. Makishima, and I. Shimomura. 2003. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X receptor. J. Biol. Chem. 278: 21344-21351. (Pubitemid 36792529)
27. Kaplan, R., T. Zhang, M. Hernandez, F. X. Gan, S. D. Wright, M. G. Waters, and T. Q. Cai. 2003. Regulation of the angiopoietin-like protein 3 gene by LXR. J. Lipid Res. 44: 136-143. (Pubitemid 36114779)
28. Ge, H., J. Y. Cha, H. Gopal, C. Harp, X. Yu, J. J. Repa, and C. Li. 2005. Differential regulation and properties of angiopoietin-like proteins 3 and 4. J. Lipid Res. 46: 1484-1490. (Pubitemid 43109813)
29. ACCORD Study Group, H. N. Ginsberg, M. B. Elam, L. C. Lovato, J. R. Crouse III, L. A. Leiter, P. Linz, W. T. Friedewald, J. B. Buse, H. C. Gerstein, J. Probstfield, R. H. Grimm, F. Ismail-Beigi, J. T. Bigger, D. C. Goff, Jr., W. C. Cushman, D. G. Simons-Morton, and R. P. Bvington. 2010. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362: 1563-1574.